Qiagen (NYSE:QGEN) had its price target reduced by Morgan Stanley from $39.00 to $37.00 in a research report released on Wednesday, April 11th. Morgan Stanley currently has an overweight rating on the stock.
Separately, DZ Bank reaffirmed a neutral rating on shares of Qiagen in a report on Thursday, April 5th.
Shares of NYSE:QGEN opened at $33.08 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.59. The firm has a market capitalization of $7,534.00, a P/E ratio of 25.99, a P/E/G ratio of 2.05 and a beta of 1.02. Qiagen has a 12-month low of $28.49 and a 12-month high of $36.34.
Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.01. The firm had revenue of $396.86 million during the quarter, compared to the consensus estimate of $394.48 million. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. equities research analysts predict that Qiagen will post 1.34 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.thelincolnianonline.com/2018/04/19/qiagen-qgen-price-target-lowered-to-37-00-at-morgan-stanley.html.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.